Results 41 to 50 of about 190,806 (273)

Radiomics-based models to predict IDH mutation status and prognosis in gliomas using MRI: a multicenter study

Frontiers in Oncology
IntroductionGliomas are infiltrative primary intracranial tumors with marked biological and clinical heterogeneity. Prognosis varies widely and depends on tumor grade, histopathological characteristics, and molecular alterations. Isocitrate dehydrogenase
Esra Sümer-Arpak, Esra Sümer-Arpak, Ayca Ersen Danyeli, Ayca Ersen Danyeli, M. Cengiz Yakicier, M. Necmettin Pamir, M. Necmettin Pamir, Koray Özduman, Koray Özduman, Alp Dinçer, Alp Dinçer, Esin Ozturk-Isik, Esin Ozturk-Isik   +12 more
doaj   +1 more source

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia

Biomarker Research, 2019
Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle. IDH mutation produces a neomorphic enzyme, which can lead to the abnormal accumulation of R-2-HG and ...
Xiaoyan Liu, Yuping Gong
doaj   +1 more source

The equilibrium constant of the isocitrate dehydrogenase reaction [PDF]

Biochemical Journal, 1968
1. The equilibrium constant for oxidative decarboxylation of isocitrate by NADP+, catalysed by isocitrate dehydrogenase, was measured in solutions of various ionic strengths and at several temperatures. 2. Thermodynamic values for the reaction were obtained by extrapolation to zero ionic strength, and the heat of reaction was estimated. 3.
J C, Londesborough, K, Dalziel
openaire   +2 more sources

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism

Frontiers in Endocrinology, 2020
Aim: Isocitrate dehydrogenase 1 (IDH1) is key enzyme involved in cellular metabolism and DNA repair. Mutations in IDH1 occur in up to 25% of cholangiocarcinomas.
Li Su, Xinglong Zhang, Lei Zheng, Miaomiao Wang, Zhifa Zhu, Ping Li   +5 more
doaj   +1 more source

Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma—A Case Report and Systematic Review

Current Issues in Molecular Biology, 2022
Both IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2) mutations play a vital role in the development of gliomas through disruption of normal cellular metabolic processes.
Alexander Yuile, Laveniya Satgunaseelan, Joe Wei, Marina Kastelan, Michael F. Back, Maggie Lee, Heng Wei, Michael E. Buckland, Adrian Lee, Helen R. Wheeler   +9 more
doaj   +1 more source

APOBEC3 activity and DNA polymerase‐ε deficiency are associated with distinct IDH1 R132 hotspot mutations

Molecular Oncology, EarlyView.
Isocitrate dehydrogenase 1 (IDH1) mutations are highly recurrent in multiple human cancer types, including cholangiocarcinoma and glioma. IDH1 R132C is the most common IDH1 mutation in cholangiocarcinoma and likely arises from APOBEC3A‐ or APOBEC3B‐mediated deamination.
Kelly E. Butler, Bilal A. Lone, Ecem Unal, A. Rouf Banday   +3 more
wiley   +1 more source

Adjunctive perampanel for glioma-associated epilepsy

Epilepsy and Behavior Case Reports, 2018
Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy.
Anastasie M. Dunn-Pirio, Sarah Woodring, Eric Lipp, James E. Herndon, II, Patrick Healy, Mallika Weant, Dina Randazzo, Annick Desjardins, Henry S. Friedman, Katherine B. Peters   +9 more
doaj   +1 more source

Mutasi Isocitrate Dehydrogenase 1 dan 2 pada Glioma

JBN (Jurnal Bedah Nasional), 2020
Klasifikasi tumor sistem saraf pusat WHO terakhir didasarkan atas histogenesis tumor dan karakteristik molekuler genetik. Perubahan klasifikasi yang paling signifikan terjadi pada tumor glioma difus yang paling signifikan, yaitu katagori tumor secara ...
Ni Putu Sriwidyani
doaj   +1 more source

Clinical Impact of MGMT Promoter Methylation in IDH‐Mutant Gliomas: Influence of Threshold Selection and Clinical Confounding

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background The clinical relevance of MGMT promoter methylation in IDH‐mutant gliomas remains controversial in the era of molecular classification. We aimed to systematically evaluate its clinical relevance by integrating quantitative assessment, cutoff exploration, and adjustment for clinical confounding.
Haihui Jiang, Linxi Cao, Xiaodong Chen, Siqi Tong, Qinghui Zhu, Jun Yang, Song Lin, Yong Cui   +7 more
wiley   +1 more source

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

Frontiers in Oncology, 2019
The identification of heterozygous neomorphic isocitrate dehydrogenase (IDH) mutations across multiple cancer types including both solid and hematologic malignancies has revolutionized our understanding of oncogenesis in these malignancies and the ...
Danielle Golub, Danielle Golub, Nishanth Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Karen Tang, Aram S. Modrek, Dimitris G. Placantonakis, Dimitris G. Placantonakis, Dimitris G. Placantonakis, Dimitris G. Placantonakis, Dimitris G. Placantonakis   +13 more
doaj   +1 more source